Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Tizona Therapeutics (United States)
Homepage:
tizonatx.com
Alternate names:
Tizona,
Tizona Therapeutics,
Tizona Therapeutics, Inc.
ROR:
0465c4575
OpenAlex ID:
I4405272444
Targeting CD39 in cancer
2020
·
Achim K. Moesta
, Xian-Yang Li
, et al.
·
Nature reviews. Immunology
·
360
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
2019
·
Xian-Yang Li
, Achim K. Moesta
, et al.
·
Cancer Discovery
·
289
Control of Metastases via Myeloid CD39 and NK Cell Effector Function
2020
·
Juming Yan
, Xian-Yang Li
, et al.
·
Cancer Immunology Research
·
85
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics
2021
·
Wei Chen
, Fan Yang
, et al.
·
mAbs
·
63
Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model
2017
·
Ying-Chun Shen
, Ali Ghasemzadeh
, et al.
·
Prostate Cancer and Prostatic Diseases
·
58
PDF
HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
2024
·
Mary E. Molloy
, Wade H. Aaron
, et al.
·
Molecular Cancer Therapeutics
·
52
PDF
Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism
2020
·
Bradley N. Spatola
, Alana G. Lerner
, et al.
·
mAbs
·
52
PDF
Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments
2017
·
Gordana Wozniak-Knopp
, Gerhard Stadlmayr
, et al.
·
Protein Engineering Design and Selection
·
13
Abstract 5012: Targeting CD39 with a first-in-class inhibitory antibody prevents ATP processing and increases T-cell activation
2019
·
Alana G. Lerner
, Maria Kovalenko
, et al.
·
Cancer Research
·
6
Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway
2026
·
Courtney Beers
, Robert L Ilaria
, et al.
·
Journal for ImmunoTherapy of Cancer
·
5
PDF
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.
2024
·
Susanna Varkey Ulahannan
, Thomas Urban Marron
, et al.
·
Journal of Clinical Oncology
·
4
US immigration order strikes against biotech
2017
·
Jeremy M Levin
, Steven H Holtzman
, et al.
·
Nature Biotechnology
·
3
570 TTX-080, a first-in-class HLA-G specific antagonist, increases distinct innate and adaptive immune cells in the tumor microenvironment and periphery
2025
·
Courtney Beers
, Megan Welch
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
698 Targeting HLA-G-mediated immunosuppression with a first-in-class antagonist antibody
2020
·
Douglas Hodges
, Christina Kochel
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
Abstract 5012: Targeting CD39 with a first-in-class inhibitory antibody prevents ATP processing and increases T-cell activation
2019
·
Alana G. Lerner
, Maria Kovalenko
, et al.
·
Immunology
·
2
Show more works
View as search
Works count:
15
Citation count:
996
Year
Topic
Type